Novo Nordisk AS's chief science officer believes the Danish diabetes fighter will claw back - and keep - bigger shares of an expanding diabetes market in coming years with new products, notably with its GLP-1 agonist semaglutide, which has patent protection until 2031 and is currently being tested in oral form.
The Denmark-based company has seen its US market share slip recently amid increased pricing pressures and stiff competition to its once-daily Victoza (liraglutide) from once-weekly products, like Eli Lilly & Co
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?